Natco Pharma has made a bold move to enter the African market with a firm ZAR 4 billion (₹2,000 crore) cash offer to acquire a 34.95% stake in South African drugmaker Adcock Ingram Holdings Limited (AIHL). The Hyderabad-based company has set the stage for a significant expansion in one of the world’s fastest-growing pharmaceutical markets.
Strategic Entry into South Africa
If successful, Natco will purchase the stake from minority shareholders at ZAR 75 ($4.271) per share, increasing its total holding to 35.75%, including its existing 0.80% stake. This will position Natco as the second-largest shareholder, behind the Bidvest Group, which holds 64.25%. The deal offers Natco a gateway into South Africa. AIHL commands 10% of the private pharmaceutical market and leads in hospital and critical-care product supply.
Deal Structure and Timeline
Natco expects to close the transaction within four months, subject to regulatory approvals. Once the deal closes, Natco will delist Adcock Ingram from the Johannesburg Stock Exchange (JSE) and operate it as a private South African company. Natco will also consolidate 35.75% of AIHL’s net profit into its financial statements to reflect its increased shareholding.
Mutual Growth Opportunities
Rajeev Nannapaneni, CEO and Vice Chairman of Natco Pharma, emphasized, “This transaction will allow Natco to tap into new revenue streams and expand our footprint in one of the largest and fastest-growing emerging markets.” For AIHL, the partnership brings access to Natco’s R&D expertise and regulatory know-how. It also offers global marketing reach, strengthening AIHL’s leadership in South Africa and supporting future regional expansion.
AIHL’s Market Standing
As reported by business-standard.com, AIHL is valued at approximately ZAR 11 billion ($632 million). It reported revenues of ZAR 9.6 billion ($536 million) for the financial year ending June 2024. Andrew Hall, CEO, AIHL, highlighted, “AIHL will gain from a partnership with a research-driven, vertically integrated pharmaceutical company. Over time, South Africans will enjoy wider access to affordable medicines.”
